Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory disease.
Confluence’s innovative KINect Technology Platform enables the identification and development of new protein kinase drugs in a fraction of the time of other approaches. Confluence’s team of world-class drug developers has created a pipeline of drug candidates which focus on creating kinase inhibitors targeting hard-to-treat cancers. Confluence’s lead program targets the kinase TAK1, which is important in cancer cell transformation, metastasis, tumor growth and drug resistance, especially in pancreatic and other cancers such as breast and colon.